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CASE REPORT

Primary Mediastinal B-cell Lymphoma Presenting as
Chest Pain in a Young Woman and Treated with
EPOCH-R*
Chloe Weidenbaum a,b,*, Akanksha Kushwah a,b, Ariana Geromes b, Jonathan A. Abbas b
a
b

University of Tennessee Health Science Center e Nashville, 2000 Church Street, Nashville, TN, 37236, United States
Ascension Saint Thomas, 2000 Church Street, Nashville, TN, 37236, United States

Abstract
Primary mediastinal B-cell lymphoma (PMBCL) is a rare type of diffuse large B-cell lymphoma, constituting 2e4% of
non-Hodgkin lymphomas. Here we present a case of PMBCL initially presenting as pleuritic chest pain in an otherwise
healthy 33-year-old woman. PMBCL typically presents as a large, fast-growing tumor limited to the mediastinum,
making the iliosacral involvement in this case unusual. ReCHOP is the most commonly used chemotherapy regimen,
although more aggressive therapies like EPOCH-R can spare the need for consolidative radiation therapy. PMBCL
represents one of the greatest diagnostic and therapeutic challenges in malignant hematology.
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1. Introduction

P

rimary mediastinal B-cell lymphoma (PMBCL)
is a type of diffuse large B-cell lymphoma
thought to be derived from the thymic B cell.1 It
presents a diagnostic challenge due to its overlapping
characteristics with other lymphomas.2 Here we
present a case of primary mediastinal B-cell lymphoma in a young woman treated with EPOCH-R.

2. Case
A 33-year-old female with no signiﬁcant past
medical history presented to the emergency
department with sharp, left-sided pleuritic chest
pain of 3 weeks’ duration. Initial work-up revealed
elevated D-dimer. CTA of the chest was negative for
pulmonary embolism but did show heterogeneous
soft tissue within the anterior and superior mediastinum with associated lymphadenopathy. AFP
and beta-HCG were normal. LDH was elevated at

256 U/L. At that time it was felt the mass would be
difﬁcult to biopsy by either mediastinoscopy or
bronchoscopy, and she was discharged with a plan
for repeat scanning in 4 weeks.
Two weeks later she re-presented with worsening
pleuritic chest pain though now associated with
shortness of breath and rib pain. A repeat CTA of
the chest showed enlarged mediastinal lymphadenopathy and lytic lesions involving multiple ribs
with adjacent soft tissue thickening suspicious for
neoplastic involvement.
Nuclear bone scan showed abnormal uptake
within the ribs containing the lytic lesions (Fig. 1).
Left seventh rib core biopsy revealed ﬁndings most
consistent with diffuse large B-cell lymphoma (Figs.
2 and 3). CD30 was weakly positive. A ﬂuorescence
in situ hybridization panel was negative for BCL-2,
BCL-6, or MYC rearrangement. Bone marrow biopsy was negative for malignancy. PET scan
revealed hypermetabolic activity in the anterior
mediastinum, ribs, sacrum, and iliac crest.
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Fig. 1. Nuclear bone scan showing abnormal uptake in the posterior right ninth and anterior left seventh ribs.

A ﬁnal diagnosis of primary mediastinal B-cell
lymphoma, stage IV, International Prognostic Index
(IPI) 3/5 was made.3 Following hospital discharge
she was seen by hematology and treatment with
EPOCH-R was initiated. All symptoms of shortness
of breath and rib pain were entirely resolved before
completion of the ﬁrst cycle.

3. Discussion
PMBCL is a rare lymphoma subtype and constitutes approximately 2e4% of all non-Hodgkin

lymphomas.4 The current WHO classiﬁcation distinguishes this lymphoma as a separate entity due to
its speciﬁc clinical and pathological features.5 This
disease affects mainly young adults (median age 35),
predominantly women.6 PMBCL typically presents
as a large, fast-growing tumor with invasion usually
limited to the anterior superior mediastinum, making the iliac and sacral involvement in our case
unusual and indicative of particularly rapid spread.7
Common signs/symptoms are cough, chest pain,
dysphagia, and tachypnea, which are related to
tumor mass inﬁltration or compression.
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Fig. 2. Left seventh core rib biopsy showing sheet-like proliferation of
large, atypical cells with frequent apoptosis, 400X.

Fig. 3. CD20 immunohistochemical stain showing B lymphocytes, 200X.

Diagnosis is made by clinical presentation in
conjunction with histopathological examination and
immunohistochemical staining. Initial treatment is
critical in the management of PMBCL since outcomes in relapsed or progressive disease are
notably worse.8e10 ReCHOP is the most commonly
used chemotherapy regimen, although there are
some reports on greater efﬁcacy with more aggressive regimens.4,10,11 More intense therapies such as
EPOCH-R have been shown to spare the need for
consolidative radiation therapy, hence why it was
chosen in the case of this patient.10,12e15

4. Conclusion
In summary, PMBCL is a rare and aggressive Bcell lymphoma that affects young people and represents one of the greatest diagnostic and therapeutic challenges in malignant hematology.
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